Here’s a polished English translation of the Chinese title: **”HitGen 2025 Annual Report: Revenue and Profit Both Grow, Operational Quality Steadily Improves”**

ChengduApril 28, 2026 /PRNewswire/ — On the evening of April 28, HitGen Inc. (Stock Code: 688222.SH, hereinafter referred to as “HitGen” or “the Company”) released its 2025 Annual Report and 2026 First Quarter Report. In 2025, the Company achieved operating revenue of RMB 526 million, representing a year-on-year increase of 23.09%; net profit attributable to shareholders of the parent company reached RMB 110 million, up 113.22% year-on-year; non-GAAP net profit attributable to shareholders of the parent company was RMB 113 million, up 96.27% year-on-year; net cash flow from operating activities amounted to RMB 216 million, up 69.01% year-on-year; the overall gross profit margin of the main business was 54.24%, an increase of 2.35 percentage points year-on-year. In the first quarter of 2026, the growth momentum continued, with operating revenue reaching RMB 161 million, up 50.40% year-on-year; net profit attributable to shareholders of the parent company was RMB 41.5002 million, and non-GAAP net profit attributable to shareholders of the parent company was RMB 39.6336 million, both achieving significant growth.

In 2025, the global biopharmaceutical market remained active, with customer demand showing diversified trends. HitGen actively deepened long-term collaborative relationships with global partners, leveraging efficient synergy and complementary advantages of domestic and international resources to continuously optimize its international market strategy. With more precise market positioning and a more efficient operational system, the Company further solidified its global industrial ecosystem layout. While orderly advancing commercial projects across its core technology platforms, the Company focused on transforming R&D achievements into practical application value, exploring the commercial implementation of R&D projects. On this basis, the Company’s main business revenue achieved steady growth throughout the year, and commercial conversion in the new technology business segment also made progress. Additionally, the Company and its UK subsidiary, Vernalis, collaborated to drive structural optimization of R&D investments, not only improving resource allocation efficiency but also ensuring the continuous enhancement of the Group’s technological innovation capabilities. Building on steady operational performance improvements, the Company systematically enhanced its ESG governance system in line with international and domestic standards, fully committed to sustainable development commitments, and released its first sustainability report during the year, with its overall ESG rating steadily rising.

Dr. Jin Li, Chairman and CEO of HitGen, stated: “Facing the opportunities and challenges brought by industry transformation, HitGen has always adhered to innovation-driven development, continuously expanding the boundaries of R&D capabilities and core technology applications along the new drug R&D value chain. Leveraging the profound accumulation of its trillion-compound library, the Company is accelerating the exploration of more diverse and higher-quality new drug ‘seeds,’ continuously supplying therapeutic molecules and novel tool molecules to the global pharmaceutical industry, driving a paradigm shift in drug R&D. In 2025, the Company’s overall performance demonstrated strong resilience, with significant growth in revenue, profit, and gross profit margin. This achievement is attributed to the deepening of global partnerships, the continuous consolidation of independent innovation capabilities, and the solid advancement of management efficiency optimization, laying a solid foundation for the Company’s long-term stable development. In the future, HitGen will continue to leverage its unique new molecule discovery system to provide more efficient and intelligent new molecule solutions, empowering global drug R&D with original innovation and contributing to the improvement of human health and quality of life.”

Forward-Looking Statements: The forward-looking descriptions in this annual report and first quarter report, including future plans and development strategies, involve uncertainties and do not constitute substantive commitments by the Company to investors. Investors are advised to be mindful of investment risks.

About HitGen

HitGen Inc. (Stock Code: 688222.SH) is committed to becoming a globally influential innovative biopharmaceutical company, dedicated to providing innovative treatment solutions for unmet clinical needs and contributing to the improvement of human health and quality of life. With its world-leading DEL (DNA-Encoded Library) technology as the core, the Company has expanded into drug design based on molecular fragments and three-dimensional structural information, as well as oligonucleotide-based drug R&D technology, proximity-induced drug R&D technology, and cyclic peptide-like derivative technology platforms. It has also independently developed the “DEL+AI+Automation” integrated molecular optimization platform, HAILO, building a unique new molecule discovery system that supplies therapeutic molecules and novel tool molecules to the global pharmaceutical industry. HitGen is headquartered in Chengdu, China, with subsidiaries in Cambridge, UK, and Houston, USA, and a business network spanning the globe. Through business models including new drug R&D services, transfer of projects at various stages, and future drug commercialization, HitGen has established extensive collaborations with numerous pharmaceutical companies, biotechnology companies, chemical companies, foundations, and research institutions worldwide. As of the end of 2025, the Company has empowered thousands of innovative drug R&D projects for over 600 clients globally. It holds multiple internal new drug projects at various clinical and preclinical stages. For more information, please visit www.hitgen.com.